Tesamorelin

Description

What Is Tesamorelin?

Tesamorelin acetate is a synthetic peptide corresponding to the first 44 amino acids of endogenous growth hormone‑releasing hormone (GHRH). This extended fragment retains potent biological activity, making it a strong stimulator of pituitary growth hormone (GH) release. Tesamorelin was developed to address metabolic complications in HIV patients, particularly excess visceral adipose tissue (VAT), and has been approved for this indication.

Mechanism of Action

Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, activating cyclic AMP signaling and stimulating pulsatile GH secretion. Elevated GH increases circulating insulin‑like growth factor‑1 (IGF‑1), which promotes lipolysis, protein synthesis, and tissue repair. By reducing visceral fat accumulation, Tesamorelin improves metabolic parameters and reduces cardiometabolic risk. Unlike direct GH administration, Tesamorelin preserves hypothalamic‑pituitary feedback mechanisms, offering a more physiologic approach to GH axis modulation.

Research & Clinical Data

Clinical trials have demonstrated Tesamorelin’s efficacy in reducing visceral adiposity in HIV‑associated lipodystrophy, leading to FDA approval. Studies also suggest potential benefits in non‑alcoholic fatty liver disease (NAFLD), age‑related metabolic decline, and cognitive function, though these remain investigational. Reported side effects include injection site reactions, peripheral edema, arthralgia, and transient increases in blood glucose. Long‑term safety continues to be evaluated, particularly in non‑HIV populations.

Purity & Quality

Pharmaceutical‑grade peptide drug. Certificate of Analysis available per batch. Regulatory status: FDA‑approved for HIV‑associated lipodystrophy; investigational in other contexts.

Classification & Handling Class: Synthetic GHRH analog | Sequence: 1‑44 amino acids | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: FDA‑approved (HIV lipodystrophy), investigational otherwise